Review anchor
3',5'-cyclic-AMP phosphodiesterase 4D
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
3',5'-cyclic-AMP phosphodiesterase 4D
CHEMBL288
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 3',5'-cyclic-AMP phosphodiesterase 4D as ChEMBL target CHEMBL288, mapped to UniProt Q08499. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL288
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q08499
3',5'-cyclic-AMP phosphodiesterase 4D
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why 3',5'-cyclic-AMP phosphodiesterase 4D matters
3',5'-cyclic-AMP phosphodiesterase 4D is reviewed as 3',5'-cyclic-AMP phosphodiesterase 4D (UniProt Q08499); 3',5'-cyclic-AMP phosphodiesterase 4D shows late clinical disease relevance led by fragile X syndrome. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 11 approved drugs, 4535 compounds, and 399 assays, with lead potency reaching pChEMBL 10.7.
Protein context
3',5'-cyclic-AMP phosphodiesterase 4D
3',5'-cyclic-AMP phosphodiesterase 4D Sequence length is 809 aa.
Review this target as 3',5'-cyclic-AMP phosphodiesterase 4D, mapped to UniProt Q08499. Sequence length is 809 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q08499
Protein
Disease context
fragile X syndrome
3',5'-cyclic-AMP phosphodiesterase 4D shows late clinical disease relevance led by fragile X syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include ZATOLMILAST.
Start review with fragile X syndrome because it currently carries late clinical support. Linked drugs include ZATOLMILAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 11 approved drugs, 4535 compounds, and 399 assays for this target. The dominant activity type is IC50. CHEMBL42126 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL42126 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
11 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why 3',5'-cyclic-AMP phosphodiesterase 4D matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q08499, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why fragile X syndrome is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4535
Total Compounds
399
Total Assays
11
Approved Drugs
IC50: 3615.0, KI: 155.0, EC50: 9.0, KD: 9.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL42126
|
10.7 | IC50 | Clinical |
|
|
No preferred name
CHEMBL3288029
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL3288030
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL4566742
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL1830646
|
10.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CRISABOROLE
CHEMBL484785
|
2016 |
|
|
APREMILAST
CHEMBL514800
|
2014 |
|
|
ROFLUMILAST
CHEMBL193240
|
2010 |
|
|
IBUDILAST
CHEMBL19449
|
1989 |
Source Header